对循环肿瘤DNA（ctDNA）中的端粒酶逆转录酶（TERT）重排断点进行连续定量可实现神经母细胞瘤患者的微小残留病监测。
Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma.
作者信息
Hollander Jan F, Szymansky Annabell, Wünschel Jasmin, Astrahantseff Kathy, Rosswog Carolina, Thorwarth Anne, Thole-Kliesch Theresa M, Chamorro González Rocío, Hundsdörfer Patrick, Hauptmann Kathrin, Schmelz Karin, Gürgen Dennis, Rogasch Julian M M, Henssen Anton G, Fischer Matthias, Schulte Johannes H, Eckert Cornelia, Eggert Angelika, Lodrini Marco, Deubzer Hedwig E
机构信息
Department of Pediatric Oncology and Hematology, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Department of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Cologne, Germany.
出版信息
Cancer Res Commun. 2025 Jan 1;5(1):167-177. doi: 10.1158/2767-9764.CRC-24-0569.
Real-time molecular monitoring of TERT-rearranged high-risk neuroblastoma is an unmet clinical need. We tested liquid biopsy-based assays for patient-individualized TERT breakpoint sequences to monitor disease in pediatric patients. Our digital PCR approach provides high resolution of spatial and temporal disease quantification in individual patients and is applicable for clinical routine.
对端粒酶逆转录酶（TERT）重排的高危神经母细胞瘤进行实时分子监测是一项尚未满足的临床需求。我们测试了基于液体活检的检测方法，以获取患者个体化的TERT断点序列，从而监测儿科患者的疾病情况。我们的数字PCR方法能够对个体患者的疾病进行高分辨率的时空定量分析，并且适用于临床常规检测。
Zotero 插件